WE@HealthTech
Lyora Aharonov is the Co-founder and CEO of EMRIS Pharma, with active involvement as a member of WE@HealthTech since April 2022. Aharonov was a finalist at MassChallenge Israel from February to June 2024 and previously served as Director of R&D and R&D Senior Scientist at NurExone Biologic from April 2021 to October 2023, where Aharonov was involved in the tech transfer of a spinal cord injury regeneration project. Aharonov's experience also includes roles such as Senior Research Associate at Technion, Molecular Diagnostics Project Manager at Barcode Diagnostics, and Independent Consultant at Lyora A. Life Science Consulting. Earlier positions include Molecular Biology Team Leader at Adicet Bio, Molecular Biology Coordinator at Bnai Zion Medical Center, and Laboratory Manager at Technion. Aharonov holds a PhD, MSc, and BSc in Biotechnology and Food Engineering from Technion - Israel Institute of Technology and The Hebrew University of Jerusalem.
This person is not in the org chart
WE@HealthTech
Women comprise about 70% of the HealthTech industry work force. Out of the 30 companies listed in the Biomed Index there are only two women CEOs amongst a total of sixty CEOs and Chairmen. The share value of companies that include women on their boards are higher by an average of 44% (Goldman Sachs). FORTUNE 500 companies with a larger number of women in senior management positions have better financial results (Catalyst). It follows that proper representation of women in top managerial levels will serve not only social and gender equality goals, but also organizational, business, and economic goals and performance. In partnership with 8400 we introduce a HealthTech launchpad program to promote junior women managers to executive positions throughout the ecosystem.